Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions

Abstract

RTK fusions in colorectal cancer are a rare, but important disease subgroup that occurs in <i>RAS</i> and <i>BRAF</i> wild-type tumors. Despite enrichment in acquired MMR-D tumors, RTK fusions also occur in MSS colorectal cancer and provide an important therapeutic target.